ArticlePharmaceutics2026

First-in-Human Dose Selection, Pharmacokinetics Prediction, and Clinical Validation of SYHA1805, a Novel FXR Agonist, Using Allometric Scaling and PBPK Modeling.

Lei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.